The Amarin Win: How Cahill Gordon Took On The FDA

By Jeff Overley (March 18, 2016, 4:26 PM EDT) -- When Amarin Pharma this month nailed down a seismic win for Big Pharma's off-label marketing, it was the climax of a First Amendment case painstakingly developed by three seasoned attorneys at Cahill Gordon & Reindel LLP. 

Floyd Abrams

Joel Kurtzberg

Michael Weiss The March 8 settlement with the U.S. Food and Drug Administration followed a landmark decision last year in New York federal court allowing Ireland-based Amarin Pharma Inc. to distribute truthful and nonmisleading promotional information to doctors about unapproved uses of omega-3 drug Vascepa.

That sort of promotion has long been perilous, potentially inviting criminal charges and steep financial penalties...

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!

TRY LAW360 FREE FOR SEVEN DAYS

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!